rs10038916 — GRIA1

GRIA1 and the Glutamate Receptor Locus for Restless Legs Syndrome

Deep inside your brain, the thalamus acts as a sensory relay station — filtering and routing signals between your body and cortex throughout the day, and shifting into a dampened state that allows sleep at night. In restless legs syndrome (RLS), this relay appears to malfunction: something keeps it overstimulated at exactly the moment it should be going quiet. GRIA1 encodes the GluA1 subunit of the AMPA receptor¹¹ GRIA1 encodes the GluA1 subunit of the AMPA receptor
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are the principal fast excitatory receptors in the brain, responsible for most rapid synaptic transmission, the most abundant fast-excitatory glutamate receptor in the central nervous system. A variant within this gene — rs10038916 — has now been genome-wide significantly associated with RLS risk, implicating glutamatergic hyperactivity as a core biological mechanism.

The Mechanism

rs10038916 is an intronic variant at position 153,718,534 on chromosome 5 (GRCh38), within GRIA1. It does not change the GRIA1 protein sequence directly, but intronic variants at GWAS significance typically act through regulatory effects: altering splicing patterns, enhancer activity, or expression levels of the gene in specific tissues. Elevated GRIA1 activity in thalamic circuits would increase glutamate-mediated excitatory transmission at exactly the circuits implicated in arousal.

MR spectroscopy studies have directly measured thalamic glutamate and glutamine (collectively Glx) in people with RLS and found it significantly elevated compared to controls — a Glx/creatinine ratio of 1.20 ± 0.73 versus 0.80 ± 0.39 (t=2.2, p=0.016)²² MR spectroscopy studies have directly measured thalamic glutamate and glutamine (collectively Glx) in people with RLS and found it significantly elevated compared to controls — a Glx/creatinine ratio of 1.20 ± 0.73 versus 0.80 ± 0.39 (t=2.2, p=0.016). Critically, this elevation correlated strongly with the degree of sleep disruption (r=0.61, p=0.007) but not with periodic leg movements, pointing toward glutamate as the driver of the arousal and sensory components of RLS rather than the motor component. This dissociation has mechanistic implications: it suggests the unpleasant sensations and inability to sleep that define RLS symptomatically may be governed by glutamatergic circuitry, while the leg-movement aspect may be more dopamine-driven.

The upstream trigger for this glutamate excess is brain iron deficiency³³ brain iron deficiency
even when serum iron is normal, the brain can be iron-deficient; this is measurable via ferritin in cerebrospinal fluid and correlates strongly with RLS severity. Iron is a cofactor for tyrosine hydroxylase and for adenosine synthesis; when brain iron falls, dopaminergic tone drops and the adenosine-mediated inhibitory brake on glutamate release weakens simultaneously. The result is a hyperglutamatergic state in cortico-striatal-thalamic circuits⁴⁴ hyperglutamatergic state in cortico-striatal-thalamic circuits — exactly the circuits where GRIA1 is most abundantly expressed. Individuals who carry the G allele at rs10038916 may have somewhat higher GRIA1 activity at baseline, making thalamic glutamate dysregulation easier to trigger and harder to compensate for.

Animal studies reinforce the link: complete deletion of the Gria1 gene in mice produces fragmented, misaligned rest-activity patterns, attenuated light-induced sleep suppression, and heightened but erratic responses to environmental cues⁵⁵ complete deletion of the Gria1 gene in mice produces fragmented, misaligned rest-activity patterns, attenuated light-induced sleep suppression, and heightened but erratic responses to environmental cues. This parallels the RLS phenotype of disrupted nocturnal sleep with increased arousal sensitivity, suggesting GRIA1 is not just a statistical hit in a GWAS but a biologically plausible node in the RLS circuit.

The Evidence

The central evidence comes from the largest RLS GWAS ever conducted⁶⁶ largest RLS GWAS ever conducted: a meta-analysis by Schormair, Zhao, Bell and colleagues (2024, Nature Genetics) pooling 116,647 individuals with RLS and 1,546,466 controls of European ancestry. This study multiplied the number of known RLS risk loci eightfold — from roughly 20 to 164. Among these 164 loci, rs10038916 at GRIA1 reached p=9.99×10⁻¹⁶, far beyond the standard genome-wide significance threshold of 5×10⁻⁸. The paper specifically highlighted GRIA1 and the related glutamate receptor gene GRIA4 as "druggable" targets, meaning they encode proteins for which modulatory compounds already exist or can be developed. This is only the second time glutamate receptor genetics have been implicated in RLS at genome-wide significance — the identification of two independent GWAS hits in AMPA receptor genes argues strongly for a genuine glutamatergic contribution to RLS biology rather than a statistical artifact.

The study also found that genetic risk factors for RLS overlap with genetic predispositions to diabetes (Mendelian randomization identified RLS as a causal risk factor for diabetes), and that sex-specific analyses showed largely overlapping genetic architecture (rg=0.96 between sexes), meaning rs10038916 is equally relevant in men and women. RLS affects approximately 5–10% of adults of European descent and is substantially heritable, with the Schormair 2024 data representing the definitive genetic architecture to date.

The G allele at rs10038916 is the minor allele in Europeans (~34%) and nearly absent in East Asians (~4%), aligning with known epidemiological observations that RLS prevalence is higher in Europeans than in East Asian populations.

Practical Implications

The genetic association points toward brain iron availability and glutamate regulation as the two modifiable targets most relevant to your genotype. Non-pharmacological approaches to RLS with glutamatergic rationale include iron optimization (brain iron deficiency is the upstream trigger for the hyperglutamatergic state) and careful attention to anything that further elevates thalamic glutamate at night — including some medications and dietary factors. Gabapentin and pregabalin, the leading non-dopaminergic drug treatments for RLS, work through α2δ calcium channel subunits that reduce presynaptic neurotransmitter release including glutamate, which may explain why they specifically address the sensory/arousal component that correlates with thalamic Glx elevation.

RLS has long been managed primarily with dopamine agonists, but the Schormair 2024 findings strengthen the scientific case for glutamate-targeting alternatives — an important development given that dopamine agonists cause augmentation (worsening symptoms) in up to 50% of long-term users.

Interactions

The most directly relevant interaction is with rs10895816 at GRIA4 — a second AMPA receptor subunit gene that also reached genome-wide significance in the same Schormair 2024 GWAS meta-analysis. GRIA1 and GRIA4 encode two of the four GluA subunits that assemble into functional AMPA receptor tetramers; variants in both genes affecting receptor properties or expression would be expected to have compounding effects on glutamatergic excitability in thalamic circuits. Users who carry the risk allele at both rs10038916 (GRIA1) and rs10895816 (GRIA4) may have a stronger glutamatergic signature than either variant alone would produce, though the combined effect has not been quantified separately in published studies.